GlassScriptPhysician profile
Srikanth Damaraju
NPI 1790785442
$21,215.15
in general payments reported to CMS, 2019-2025
33 companies · $2,980 in 2025
The $2,980 reported for 2025 was more than what 88% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,169 · 2020: $826 · 2021: $1,632 · 2022: $1,932 · 2023: $7,235 · 2024: $2,441 · 2025: $2,980.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,290 · Travel and Lodging: $4,366.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,289.69 |
| Travel and Lodging | $4,366.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $6,877.31 | 2021-2025 | Evera Mri Xt Dr Surescan, Corevalve Evolut R, Symplicity G3 |
| Abbott Laboratories | $2,498.03 | 2019-2025 | Mitraclip, Esprit, Diamondback Peripheral |
| Abiomed | $2,408.85 | 2019-2025 | Impella |
| Edwards Lifesciences Corporation | $1,571.32 | 2019-2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv), Edwards Sapien 3 Ultra Transcatheter Heart Valve, Sapien 3 Ultra Resilia |
| W. L. Gore & Associates, INC. | $1,477.53 | 2019-2025 | Gore Tag Thoracic Endoprosthesis, Gore Tag Thoracic Branch Endoprosthesis, Excluder Conformable Aaa Endoprosthesis With Active Control |
| Janssen Pharmaceuticals, INC | $1,267.24 | 2019-2024 | Xarelto |
| Boston Scientific Corporation | $1,099.91 | 2019-2022 | |
| Medtronic Vascular, INC. | $908.70 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $398.13 | 2020-2025 | |
| Pfizer INC. | $364.57 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $288.20 | 2019-2025 | Farxiga |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $285.04 | 2019-2025 | Lifevest |
| Shockwave Medical, INC | $236.22 | 2023-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $231.35 | 2021-2025 | Jardiance |
| Biotronik INC. | $173.20 | 2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $156.55 | 2023-2024 | Opsumit, Uptravi |
| Preventice Services, LLC | $126.96 | 2020 | |
| Cardiovascular Systems INC. | $124.35 | 2020-2023 | Diamondback Peripheral |
| Janssen Scientific Affairs, LLC | $104.30 | 2019 | |
| Amgen INC. | $79.51 | 2019-2025 | Repatha |
| Merck Sharp & Dohme LLC | $76.49 | 2021-2023 | Verquvo |
| Silk Road Medical, INC. | $73.02 | 2019 | |
| Endologix LLC | $69.48 | 2025 | Endocross Device, Torus Stent Graft System |
| Philips North America LLC | $60.16 | 2025 | Coronary Other |
| Esperion Therapeutics, INC. | $46.21 | 2020-2021 | |
| E.R. Squibb & Sons, L.L.C. | $41.08 | 2023-2024 | Camzyos, Eliquis |
| Angiodynamics, INC. | $37.67 | 2021 | |
| Cvrx, INC. | $35.95 | 2025 | Barostim Neo System |
| Kiniksa Pharmaceuticals International, Plc | $23.43 | 2024 | Arcalyst |
| Lexicon Pharmaceuticals, INC. | $21.46 | 2023 | Inpefa |
| Lantheus Medical Imaging, INC. | $21.18 | 2025 | |
| Irhythm Technologies, INC. | $16.25 | 2021 | |
| Cook Medical LLC | $15.50 | 2023 | Peel-Away |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Srikanth Damaraju listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.